Deanna Portero 10/27/26 Deanna Portero 10/27/26

Nonprofit resurrects shelved gene therapy after startup shuts down

OTXL identifies promising treatments that have stalled and works with partners to complete clinical development and create commercial pathways, enabling patients to access those treatments.

Dean A. Wetherbee 9/9/26 Dean A. Wetherbee 9/9/26

Orphan Therapeutics Accelerator and ASGCT Partner to Revive Shelved Ultrarare Therapies

OTXL identifies promising treatments that have stalled and works with partners to complete clinical development and create commercial pathways, enabling patients to access those treatments.

Dean A. Wetherbee 5/15/26 Dean A. Wetherbee 5/15/26

A Zillow-like marketplace for abandoned gene therapies goes live

A Zillow-like marketplace for abandoned gene therapies goes live

Dean A. Wetherbee 2/24/26 Dean A. Wetherbee 2/24/26

New Initiative Aims to Revive Stalled Rare Disease Therapies

Dean A. Wetherbee 12/24/25 Dean A. Wetherbee 12/24/25

Alternative Commercialisation Models Offer Lifeline to Future of Gene Therapies

It All Begins Here

Dean A. Wetherbee 11/19/25 Dean A. Wetherbee 11/19/25

Alternative Development & Commercialization Strategies for Rare Disease Gene Therapies

Dean A. Wetherbee 10/3/25 Dean A. Wetherbee 10/3/25

How Orphan Therapeutics Accelerator is Optimizing Rare Disease Search and Eval

Dean A. Wetherbee 4/23/25 Dean A. Wetherbee 4/23/25

How Orphan Therapeutics Accelerator is Optimizing Rare Disease Search and Eval (Copy)

Dean A. Wetherbee 3/31/25 Dean A. Wetherbee 3/31/25

Saving Shelved Ultra-Rare Therapies Through Unorthodox Funding

Dean A. Wetherbee 10/15/24 Dean A. Wetherbee 10/15/24

When a Miracle Cure is Left on the Shelf

Dean A. Wetherbee 3/20/24 Dean A. Wetherbee 3/20/24

Non-Profit Biotech Aims to Revive Stalled Ultrarare Therapies